These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 32288506)

  • 1. ICER's timelines for assessments extended due to COVID-19.
    PharmacoEcon Outcomes News; 2020; 850(1):1. PubMed ID: 32288506
    [No Abstract]   [Full Text] [Related]  

  • 2. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
    Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
    Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICER's second update to pricing models of remdesivir for COVID-19.
    PharmacoEcon Outcomes News; 2020; 867(1):2. PubMed ID: 33262564
    [No Abstract]   [Full Text] [Related]  

  • 4. Worldwide HTA access to ICER's cost-effectiveness models.
    PharmacoEcon Outcomes News; 2020; 864(1):3. PubMed ID: 33082704
    [No Abstract]   [Full Text] [Related]  

  • 5. Challenges with Forecasting Budget Impact: A Case Study of Six ICER Reports.
    Snider JT; Sussell J; Tebeka MG; Gonzalez A; Cohen JT; Neumann P
    Value Health; 2019 Mar; 22(3):332-339. PubMed ID: 30832971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICER's Revised Value Assessment Framework for 2017-2019: A Critique.
    Neumann PJ; Cohen JT
    Pharmacoeconomics; 2017 Oct; 35(10):977-980. PubMed ID: 28791663
    [No Abstract]   [Full Text] [Related]  

  • 7. Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER's Cost-Effectiveness Estimates.
    Breslau RM; Cohen JT; Ollendorf DA; Neumann PJ
    Pharmacoecon Open; 2022 Nov; 6(6):893-895. PubMed ID: 35871128
    [No Abstract]   [Full Text] [Related]  

  • 8. The transcriptional repressor ICER binds to multiple loci throughout the genome.
    Muñiz LC; Molina CA
    Biochem Biophys Res Commun; 2016 Sep; 478(3):1462-5. PubMed ID: 27590584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timelines of COVID-19 vaccines.
    Chugh T
    Curr Med Res Pract; 2020; 10(4):137-138. PubMed ID: 32839724
    [No Abstract]   [Full Text] [Related]  

  • 10. Antisense experiments reveal molecular details on mechanisms of ICER suppressing cAMP-inducible genes in rat pinealocytes.
    Pfeffer M; Maronde E; Korf HW; Stehle JH
    J Pineal Res; 2000 Aug; 29(1):24-33. PubMed ID: 10949537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of repression of the inhibin alpha-subunit gene by inducible 3',5'-cyclic adenosine monophosphate early repressor.
    Burkart AD; Mukherjee A; Mayo KE
    Mol Endocrinol; 2006 Mar; 20(3):584-97. PubMed ID: 16269517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICER evokes Dusp1-p38 pathway enhancing chemotherapy sensitivity in myeloid leukemia.
    Pigazzi M; Manara E; Beghin A; Baron E; Tregnago C; Basso G
    Clin Cancer Res; 2011 Feb; 17(4):742-52. PubMed ID: 21325296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costo Efectividad del Tratamiento de Tumores Neuroendócrinos Pancreáticos Avanzados no Operables con Sunitinib en México.
    Muciño Ortega E; Chi-Chan A; Peniche-Otero G; Gutiérrez-Colín CI; Herrera-Rojas J; Galindo-Suárez RM
    Value Health Reg Issues; 2012 Dec; 1(2):150-155. PubMed ID: 29702894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using timelines to depict patient journeys: a development for research methods and clinical care review.
    Momen N; Kendall M; Barclay S; Murray S
    Prim Health Care Res Dev; 2013 Oct; 14(4):403-8. PubMed ID: 23375351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contradictory effects of timelines on community participation in a health promotion programme.
    Batten L; Holdaway M
    Health Promot Int; 2011 Sep; 26(3):330-7. PubMed ID: 21059736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timelines Revisited: A Design Space and Considerations for Expressive Storytelling.
    Brehmer M; Lee B; Bach B; Riche NH; Munzner T
    IEEE Trans Vis Comput Graph; 2017 Sep; 23(9):2151-2164. PubMed ID: 28113509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using timelines as part of recovery-focused practice in psychosis.
    Marland G; McNay L; Fleming M; McCaig M
    J Psychiatr Ment Health Nurs; 2011 Dec; 18(10):869-77. PubMed ID: 22070773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium difficile intervention timelines for diagnosis, isolation, and treatment.
    Champredon D; Zhang K; Smieja M; Moghadas SM
    Am J Infect Control; 2019 Nov; 47(11):1370-1374. PubMed ID: 31182236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timelines of translational science: From technology initiation to FDA approval.
    McNamee LM; Walsh MJ; Ledley FD
    PLoS One; 2017; 12(5):e0177371. PubMed ID: 28481922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better?
    Mitchell JD; Callagher P; Gardham J; Mitchell C; Dixon M; Addison-Jones R; Bennett W; O'Brien MR
    Amyotroph Lateral Scler; 2010 Dec; 11(6):537-41. PubMed ID: 20565332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.